Patents Assigned to Assistance Publique-Hopitaux de Paris
  • Device for administering a radiopharmaceutical drug
    Patent number: 10814141
    Abstract: An administration device that includes a hermetic container closed by a cap, containing a radiopharmaceutical medicament, and provided with a protective shield made of a radiopaque material. The device includes a support provided with attachment structure. The container is removably attached to the support in a position allowing access to the cap. The support includes a baseplate provided with an opening allowing access to the cap. A cover and rods connect the baseplate and the cover.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: October 27, 2020
    Assignee: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Christian Starz, Philippe Darras, Hervé Caradec, Makrem Ben Reguiga
  • Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject
    Patent number: 10801040
    Abstract: The present invention relates to methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject. In particular, the present invention relates to a method for selectively expressing a polynucleotide of interest in the peripheral nervous system of a subject in need thereof comprising the step of transducing a peripheral nerve of the subject with an amount of an AVV9 vector containing the polynucleotide of interest.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: October 13, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE PARIS-SUD, COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ DE MONTPELLIER
    Inventors: Patrick Aubourg, Nicolas Tricaud, Benoît Gautier
  • INTERLEUKIN-17 PATHWAY INHIBITOR FOR THE TREATMENT OF CHRONIC HPV INFECTIONS
    Publication number: 20200308269
    Abstract: Embodiments of the disclosure relate to the use of an IL-17 pathway inhibitor for treating chronic infections caused by one or more HPVs.
    Type: Application
    Filed: May 24, 2017
    Publication date: October 1, 2020
    Applicants: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS DIDEROT - PARIS 7
    Inventors: Vincent Descamps, Florence Brunet-Possenti
  • Allergen desensitization method
    Patent number: 10758610
    Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: September 1, 2020
    Assignees: DBV Technologies, Assistance Publique Hopitaux De Paris, Universite Paris Descartes
    Inventors: Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
  • PROCESS FOR MULTI-ANALYSES OF RARE CELLS EXTRACTED OR ISOLATED FROM BIOLOGICAL SAMPLES THROUGH FILTRATION
    Publication number: 20200264166
    Abstract: A process for isolating or extracting rare cells from a biological sample comprising filtering a biological sample, which may be treated or diluted, through a filter that has a pore size, pore density or other physical properties that retain rare cells, but which permits other kinds of cells to pass through the filter. This process also comprises multiple analyses performed on rare cells after their extraction or isolation by filtration to diagnostically identify the presence of rare cells in a biological sample and to use their diagnostic identification and molecular characterization for diagnostic purposes such as for early diagnosis of diseases, namely for early diagnosis of cancer and to select, guide, monitor treatments and in particular to select targeted treatments and to monitor the response and/or resistance to them.
    Type: Application
    Filed: January 17, 2020
    Publication date: August 20, 2020
    Applicants: RARECELLS SAS, UNIVERSITE DE NICE SOPHIA ANTIPOLIS, CENTRE HOSPITALIER UNIVERSITAIRE DE NICE, UNIVERSITE PARIS DESCARTES, Assistance Publique-Hopitaux de Paris (AP-HP), Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Patrizia PATERLINI-BRECHOT, Paul HOFMAN, Sophie Marie Genevieve LAGET, Thierry CAPIOD
  • COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE RELATED CONDITIONS AND OBESITY.
    Publication number: 20200253889
    Abstract: The invention pertains to a compound of formula (I), one of its pharmaceutically acceptable salts, or a composition comprising thereof, for use in the prevention or treatment of glucose intolerance related conditions, insulin deficit related conditions, nonalcoholic fatty liver disease and/or obesity.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 13, 2020
    Applicants: SORBONNE UNIVERSITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS, KYOTO UNIVERSITY
    Inventors: Dominique Gauguier, Fumihiko Matsuda, François Brial
  • Pharmaceutical compositions for preventing or treating inflammatory bowel diseases
    Patent number: 10736927
    Abstract: The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: August 11, 2020
    Assignees: INSERM (INSTITUTE NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6), INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
    Inventors: Harry Sokol, Mathias Lavie-Richard, Marie-Laure Michel, Bruno Michel Lamas, Philippe Langella
  • METHODS FOR PREDICTING THE OUTCOME OF A CANCER IN A PATIENT BY ANALYSING GENE EXPRESSION
    Publication number: 20200248269
    Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.
    Type: Application
    Filed: December 2, 2019
    Publication date: August 6, 2020
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN
  • Methods and compositions for treating and preventing HIV
    Patent number: 10722572
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: July 28, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, BAYLOR RESEARCH INSTITUTE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections
    Patent number: 10724095
    Abstract: The invention provides diagnostic markers of immunosenescence and methods of identifying individuals with impaired immune function based on the expression level of a combination of such markers in a biological sample obtained from said individual. Such combination of markers is useful for determining the susceptibility to nosocomial infections of an individual. Such combination of markers is also useful for predicting whether an individual will respond to active vaccination and become protected against recurring diseases.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: July 28, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE
    Inventors: Sophie Hue, Yves Levy
  • PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS
    Publication number: 20200163916
    Abstract: Probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in the subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.
    Type: Application
    Filed: July 13, 2018
    Publication date: May 28, 2020
    Applicants: PARIS SCIENCES ET LETTRES - QUARTIER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITÉ, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA), UNIVERSITE DE PARIS
    Inventors: Nathalie ROUACH, Eléna DOSSI, Gilles HUBERFELD
  • TET2 as a diagnostic and prognostic marker in hematopoietic neoplasms
    Patent number: 10662482
    Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: May 26, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, UNIVERSITE PARIS DESCARTES, UNIVERSITY PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITE PARIS-SUD
    Inventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
  • Methods and pharmaceutical compostions for treating rhabdomyolysis
    Patent number: 10653687
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating rhabdomyolysis.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: May 19, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FONDATION IMAGINE, UNIVERSITÉ PARIS DESCARTES ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pascale De Lonlay-Debeney, Corinne Lebreton, Yamina Hamel, Francois-Xavier Mauvais, Peter Van Endert
  • HLA-G TRANSCRIPTS AND ISOFORMS AND THEIR USES
    Publication number: 20200148743
    Abstract: Embodiments of the disclosure pertain to the field of HLA-G molecules and their therapeutic use. The disclosure pertains to new HLA-G isoforms, that is to say new RNA transcripts and proteins deriving from the HLA-G gene, pharmaceutical composition comprising thereof, as well as primers specific of these transcripts and antibodies specific of these proteins. The disclosure further pertains to the diagnostic or therapeutic use of these molecules.
    Type: Application
    Filed: July 24, 2018
    Publication date: May 14, 2020
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Edgardo D. Carosella, Diana Tronik-Le Roux, Jean-Philippe Deslys, Jérôme Verine, François Desgrandchamps, Nathalie Rouas-Freiss, Joël Le Maoult
  • Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1
    Patent number: 10647752
    Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: May 12, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Medicale), Fondation Imagine, Assistance Publique-Hopitaux de Paris (APHP), Université Paris Descartes, Centre National de la Recherche Scientifique (CNRS), Université de Bourgogne, CNAM—Conservatoire National des Arts at Metier
    Inventors: Zakia Belaid-Choucair, Olivier Hermine, Matthieu Montes, Carmen Garrido-Fleury, Renaud Seigneuric, Guillaume Marcion
  • Method for fat characterization using MRI images acquired using a multiple gradient-echo sequence with bipolar gradients
    Patent number: 10646134
    Abstract: It is proposed a method for post-processing images of an region of interest in a subject, the images being acquired with a magnetic resonance imaging technique, the method for post-processing comprising at least the step of: —unwrapping the phase of each image, —extracting a complex signal over echo time for at least one pixel of the unwrapped images, and —calculating fat characterization parameters by using a fitting technique applied on a model, the model being a function which associates to a plurality of parameters each extracted complex signal, the plurality of parameters comprising at least two fat characterization parameters, the magnitude error and the phase error generated by the use of the bipolar readout gradients, the fitting technique being a non-linear least-square fitting technique using pseudo-random initial conditions.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: May 12, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE VERSAILLES SAINT-QUENTIN-EN-YVELINES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Benjamin Leporq, Simon Lambert, Bernard Van Beers
  • Identification of a JAK2 Mutation in Polycythemia Vera
    Publication number: 20200140863
    Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
    Type: Application
    Filed: January 6, 2020
    Publication date: May 7, 2020
    Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUD
    Inventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
  • METHOD FOR DETERMINING THE POTENTIAL EFFICACY OF ANTICANCER TREATMENT
    Publication number: 20200129566
    Abstract: Embodiments of the present disclosure relate to methods for ex vivo determining whether a patient with metastatic melanoma is likely to benefit from a treatment with an anti CTLA-4 molecule, preferably ipilimumab, by analyzing the gut microbiota in a fecal sample from said patient.
    Type: Application
    Filed: March 22, 2018
    Publication date: April 30, 2020
    Applicants: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, UNIVERSITE PARIS-SUD, INSTITUT GUSTAVE ROUSSY
    Inventor: Franck Carbonnel
  • Methods and compositions for treating and preventing HIV
    Patent number: 10610585
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: April 7, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Baylor Research Institute, Universite Paris Est Creteil Val De Marne, Assistance Publique Hopitaux de Paris
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Device for the collection, pre-analytic treatment, transport and grinding of solid samples
    Patent number: 10611522
    Abstract: The invention relates to a device for the collection, pre-analytic treatment, transport and grinding of solid samples, comprising a flask (1) having an opening (11) closed by a removable stopper (2), for receiving a solid sample. Said flask contains a pre-analytic medium (4), a plurality of balls (3) consisting of a solid material, and a means for holding the balls in place, that is designed to lose its effect when the flask is mechanically shaken or closed by the stopper, in such a way that, when the flask is mechanically shaken, the impact of the balls causes the grinding of the solid sample and the mixing thereof with the pre-analytic medium.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: April 7, 2020
    Assignees: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, THE UNIVERSITY OF VERSAILLES SAINT-QUENTIN-EN-YVELINES
    Inventor: Martin Rottman